Florida Medical Marijuana Sales Hit 15.94 Billion mg THC in 2026

Florida OMMU released 2026 aggregate dispensing data showing 15.94 billion mg of THC sold statewide.

The Office of Medical Marijuana Use published cumulative sales metrics for calendar year 2026, documenting 15.94 billion milligrams of THC dispensed across all product forms. Flower sales totaled 5.47 million ounces. The data reflect transactions at state-licensed Medical Marijuana Treatment Centers serving Florida's registry of qualified patients.

Florida Statutes §381.986 requires OMMU to track milligrams of THC as the primary unit of measure for non-flower products, while flower is reported by weight in ounces. The bifurcated reporting structure aligns with the statute's definition of "medical marijuana" encompassing both smokable flower and THC-infused preparations.

Flower accounted for 5.47 million ounces of the total 2026 dispensing volume.

Smokable flower represented 5.47 million ounces dispensed in 2026. Florida authorized smokable flower sales in March 2019 following voter approval of Amendment 2 in 2016 and subsequent legislative action under Senate Bill 182. Since that 2019 policy change, flower sales have grown consistently and now comprise a substantial share of total patient purchases by weight.

The 2026 flower total reflects continued patient preference for inhalable forms despite the availability of concentrates, tinctures, and edibles. OMMU doesn't publish revenue figures, but milligram and ounce data allow operators and investors to model gross sales using prevailing per-unit prices.

THC-milligram reporting captures concentrates, edibles, tinctures, and topicals under a single metric.

The 15.94 billion milligrams of THC dispensed include all non-flower product categories: vaporizer cartridges, concentrates, oral tinctures, edibles, and topicals. Florida's regulatory framework mandates that each product label display total THC content in milligrams, enabling OMMU to aggregate across diverse formulations.

This metric doesn't distinguish between THCA and delta-9-THC, as Florida's medical rules treat total THC as the controlling measure for dosage caps and dispensing limits. Patients face a 2.5-ounce flower cap per 35-day period and a separate milligram cap for non-flower products, both enforced through the state's Medical Marijuana Use Registry.

The 2026 figures arrive as Florida voters prepare to decide Amendment 3 in November 2026.

Florida's 2026 medical sales data land in the final weeks before the November 2026 general election, when voters will consider Amendment 3 to legalize adult-use cannabis. If Amendment 3 passes with 60 percent approval, the state's existing vertical-license Medical Marijuana Treatment Centers would be positioned to serve both medical and adult-use markets under a dual-track framework.

The 15.94 billion mg THC figure provides a baseline for modeling adult-use demand. Industry analysts typically estimate adult-use sales at 2.5 to 4 times medical volume in states with established medical programs, though Florida's large population and tourist traffic could drive higher multiples.

Florida's vertical-license structure limits market participation to 25 statewide operators.

Florida operates under a vertical-integration model codified in §381.986, under which each Medical Marijuana Treatment Center holds a single statewide license authorizing cultivation, processing, and retail. Twenty-five licenses are active as of 2026. The statute doesn't mandate additional license issuance, leaving expansion to legislative discretion.

The vertical-license cap creates a high barrier to entry. It concentrates market share among incumbent operators. Trulieve, Curaleaf, and Verano are the three largest license holders by dispensary count, collectively operating over half of Florida's approximately 600 medical dispensaries.

Next data release expected in January 2027 covering fourth-quarter 2026 dispensing activity.

OMMU publishes quarterly updates to the Medical Marijuana Use Registry, typically within 45 days of quarter-end. The next dataset will cover October through December 2026 and is expected in mid-January 2027. That release will also reflect any early post-election shifts in patient enrollment if Amendment 3 passes in November.

For full background on Florida's medical marijuana regulatory framework and Amendment 3, see the CannIntel topic hub on Florida Medical Marijuana Program.